Click here to view online. Add this email to your safelist.
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
7 June 2017
AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca’s strategic focus.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
